Professor Paul Martin
Professor of Sociology, (BA (Hons), MSc, DPhil)
Head of Department
Room: Elmfield, G34 | Telephone: 0114 222 6414 (external), 26414 (internal)
I joined the Department in March 2012 to take up the position of Chair in Sociology and Director of Research. I was formerly the Director of the Institute for Science and Society at the University of Nottingham.
I have two main areas of research interest. The first is the ethical, legal and social issues associated with emerging medical technologies and the second focuses on the commercialisation of biotechnology and expectation dynamics in medical innovation. My research has previously examined the development of gene therapy, genomics, pharmacogenetics, stem cells and regenerative medicine. I have advised the European Parliament, the Conseil d'Analyse Economique (part of the French Prime Minister's Office), the UK Department of Trade and Industry and the Wellcome Trust. I am a member of the Editorial advisory Boards of Sociology of Health and Illness and New Genetics and Society.
As regards my research interests in synthetic biology, I am currently a member of a BBSRC working group on synthetic biology, a co-investigator in a recently established multidisciplinary chell network and have co-authored a major review of the social and ethical issues raised by synthetic biology which was published in June 2008.
As regards my research interests in neuroscience, I am leader of a strand of research on neurosociety as part of the £1.6m Leverhulme Trust Programme Grant 'Making Science Public'.
|Recent Funded Research Projects|
A five-year research programme funded by the Leverhulme Trust (2012-2017) looking at the challenges involved in making science more public; how are attempts to do so changing the relationship between science, politics and publics, and what are the normative implications for problems relating to political legitimacy, scientific authority and democratic participation?
- SCS1017 Science, Technology and Society
- SCS3034 What it means to be Human
To find out more about our PhD programmes, go to:
Studying for a PhD in Sociology
Publications since 2005
Moffatt, F., Timmons, S., & Martin, P. (2013). Constructing notions of healthcare productivity: The call for a new professionalism?. Sociology of Health and Illness. doi:10.1111/1467-9566.12093
Pickersgill, M.D., Martin, P.A. and Cunningham-Burley, S. (2011) ‘Constituting Neurologic Subjects: Neuroscience, Subjectivity, and the Mundane Significance of the Brain’, Subjectivity, 4(3):346-365. doi: 10.1057/sub.2011.10
Williams SJ, Martin P, Gabe J. (2011) 'Evolving sociological analyses of 'Pharmaceuticalisation': A reply to Abraham', Sociology of Health and Illness 33(5):729-730. doi: 10.1111/j.1467-9566.2011.01396.x
Williams, S. J., Martin, P. and Gabe, J. (2011), The pharmaceuticalisation of society? A framework for analysis. Sociology of Health and Illness, 3(5):710-725: doi: 10.1111/j.1467-9566.2011.01320.x
Plagnol, A.C., Rowley, E., Martin, P. and Livesey, F. (2009) Industry perceptions of barriers to commercialization of regenerative medicine products in the UK. Regenerative Medicine 4(4):549-559 [Cit: 4]
Calvert, J. And Martin, P. (2009) The role of social science in synthetic biology. EMBO Reports, 10(3):201-204. [Cit: 10]
England, T.J, Martin, P., and Bath, P.M.W. (2009) Stem cells for enhancing recovery after stroke: a review. International Journal of Stroke 4:101-110 [Cit: 9]
Coveney, C.M., Nerlich, B., and Martin, P.A. (2009) Modafinil in the media: metaphors, medicalisation and the body. Social Science and Medicine. 68(3):487-95 [Cit: 8]
Williams, S. and Martin, P.A. (2009) Drug induced cognitive enhancement and society. Frontiers in Neuroscience. 3(1)
Martin, P.A., and Balmer, A. (2008) Synthetic Biology: Social and Ethical Challenges. September 2008. Available from http://www.bbsrc.ac.uk/organisation/policies/reviews/scientific-areas/0806-synthetic-biology.aspx
Tutton R, Smart A, Martin P.A., Ashcroft R, Ellison GTH. (2008) Genotyping the future: scientists' expectations about race/ethnicity after BiDil®. Journal of Law, Medicine and Ethics 36 (3) 464-470 [Cit: 8]
Martin, P., Brown, N., and Turner, A. (2008) Capitalising hope: the commercial development of umbilical cord blood stem cell banking. New Genetics and Society. 27(2): 127-143 [Cit: 4]
Weiner, K. and Martin, P.A. (2008) A genetic future for coronary heart disease. Sociology of Health and Illness. 30 (3): 380-395. [Cit: 10]
Ellison GTH, Tutton R, Outram SM, Martin P., Ashcroft R, Smart A. (2008) An interdisciplinary perspective on the impact of genomics on the meaning of 'race', and the future role of racial categories in biomedical research. NTM Journal of the History of Science, Technology and Medicine 16: 378-386. [Cit: 1]
Ellison, G.T.H., Kaufman, J.S., Head, R.F., Martin, P.A. and Kahn, J.D. (2008) Flaws in the U.S. Food and Drug Administration’s Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients. Journal of Law, Medicine and Ethics. 36(3): 449-457 [Cit: 7]
Smart, A., Tutton, R., Ashcroft, R., Martin, P.A., Balmer, A., Elliot, R. and G.T.H. Ellison (2008) Social Inclusivity vs. Analytical Acuity? A Qualitative Study of UK Researchers Regarding the Inclusion of Minority Racial/Ethnic Groups in Biobanks. Medical Law International, 9(2): 169-190 [Cit: 2]
Martin, P.A., Brown, N and Kraft, A. (2008) From bedside to bench? Communities of Promise, Translational Research and the Making of Blood Stem Cells. Science as Culture. 17(1):29-42. [Cit: 10]
Smart, A., Tutton, R., Martin, P.A., Ellison, G. T. H. and Ashcroft, R. (2008) The Standardisation of Race and Ethnicity in Biomedical Science Editorial and UK Biobanks. Social Studies of Science. 38(3): 407-423 [Cit: 15]
Ellison, G.T.H., Smart, A., Tutton, R., Outram, S.M., Ashcroft, R. and Martin, P. (2007) Racial categories in medicine: a failure of evidence-based practice? PLoS 4(9): 1434-1436 [Cit: 21]
Hopkins, MH., Martin, PA., Nightingale, P., Kraft, A. and Mahdi, S. (2007) The Myth of the Biotech Revolution: An assessment of technological, clinical and organisational change. Research Policy 36(4): 566-589 [Cit: 67]
Hopkins, M.M. and Martin, P.A. (2006) Role of pharmacogenetics in the use of CNS drugs: from drug pipeline to primary care? (editorial). Expert Review of Neurotherapeutics 6(12):1765-1767 [Cit: 1]
Martin, PA., Coveny, C., Kraft, A., Brown, N and Bath, P (2006) The commercial development of stem cell technology: lessons from the past, strategies for the future. Regenerative Medicine 1(6): 801-807 [Cit: 11]
Smart, A.; Tutton, R., Ashcroft, R., Martin, P.A. and Ellison, G.T.H. (2006) Can Science Alone Improve the Measurement and Communication of Race and Ethnicity in Genetic Research? Exploring the Strategies Proposed by Nature Genetics. BioSocieties 1(3):313-324 [Cit: 11]
Brown, N., Kraft, A. and Martin. P. (2006) The Promissory Pasts of Blood Stem Cells. BioSocieties. 1(3):329-348 [Cit: 7]
Hopkins, MM., Ibarreta, D., Gaisser, S., Enzing, CM., Ryan, J., Martin, PA., Lewis, G., Detmar, S., van den Akker-van Marle, ME., Hedgecoe, AM., Nightingale, P., Dreiling, M., Hartig, KJ., Vullings, W. and Forde, T. (2006) Putting pharmacogenetics into practice. Nature Biotechnology 24 (April): 403-410 [Cit: 52]
Smart, A. and Martin, P.A. (2006) The promise of pharmacogenetics: Assessing the prospects for disease and patient stratification. Studies in the History and Philosophy of Biological and Biomedical Sciences. 37(3):583-601 [Cit: 6]
Busby, H. and Martin, P.A. (2006) Biobanks, national identity and imagined genetic communities: the case of UK biobank. Science as Culture. 15(3):237-251. [Cit: 16]
Martin, P (2005) The paradox of race/ ethnicity (response to Ellison). Critical Public Health. 15(1): 77-78 [Cit: 3]
A full list of publications can be downloaded by clicking the link on the right of this page.